“Bendamustine Is a Hybrid Antimetabolite and Alkylating Agent Offering New Therapeutic Options for the Treatment of Non-Hodgkin Lymphomas”. Hematology Meeting Reports (formerly Haematologica Reports) 2, no. 5 (June 23, 2009). Accessed June 20, 2025. https://journals.pagepress.org/hmr/article/view/749.